Exelixis, Inc.
Exelixis, Inc. is a biopharmaceutical company focused on developing cancer therapies, with a primary political signal being a single lobbying pattern linked to Rep. Ro Khanna (D-CA) on defense issues related to cancer drug access, despite $0 lobbying income reported in 2024.
BusinessWhat EXEL does
Exelixis is a biopharmaceutical company that discovers, develops, and commercializes targeted therapies for cancer treatment. Its revenue is primarily driven by sales of its flagship product, cabozantinib, marketed as CABOMETYX for various advanced cancers. The company also engages in partnerships and licensing agreements to expand its pipeline and commercial reach.
12 months past · 3 months futureEXEL activity timeline
Executive Branch ConflictsEXEL held by Trump-administration officials
Lifetime Government AwardsEXEL federal contracts
EXEL doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Congressional TradesWho in Congress is trading EXEL
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting EXELLive legislation impacting this stock
Political ProfileWhere EXEL sits in Washington
[object Object]
STRUCTURAL: Single lobbying pattern aligned with House Armed Services Committee on defense issues related to cancer drugs, but $0 lobbying income and no federal contracts. EVIDENTIARY: No corporate insider buys (tier F, 0 buys), no congressional traders, but executive branch exposure shows Trump holds EXEL stock and dividends. Net: Mixed signals with limited scale.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Potential changes to drug pricing, coverage, and payment under defense-related healthcare policiesDepartment of Defense, Centers for Medicare & Medicaid Services"get_political_influence.lobbying_patterns[0].committees includes HSAS (House Armed Services) and lobbying filings mention 'access, coverage, and payment for cancer drugs' under defense issue area."
Regulatory opportunities
-
Advocacy for improved access and coverage of cancer drugs through defense health programsDepartment of Defense"get_political_influence.lobbying_patterns[0].matches_committee true for HSAS, and lobbying filings focus on defense issues related to cancer drugs."
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
LobbyingWho's hired to advocate for EXEL
Live signals + predictions for EXEL — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades EXEL
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord